Our work demonstrates that elevated levels of STEAP1 EVs are significantly associated with a PCa diagnosis, suggesting that quantitation of STEAP1 EVs could be used as a screening platform to improve the selection of individuals for follow-up biopsy. Here, STEAP1 is linked to posterior cortical atrophy.